Sample Type for Germline BRCA1/2 Testing in Ovarian Cancer
For germline BRCA1/2 mutation testing in ovarian cancer, use a peripheral blood sample (or alternatively saliva/buccal swab), as germline testing analyzes DNA from all cells in the body, not tumor tissue. 1
Understanding the Distinction: Germline vs. Somatic Testing
The key to answering this question is understanding that germline and somatic testing require different sample types:
Germline Testing (Blood/Saliva Sample)
- Sample source: Peripheral blood, saliva, or buccal swab
- What it detects: Inherited mutations present in all cells of the body
- Purpose: Identifies hereditary cancer risk for the patient and family members
- Recommendation: All women with epithelial ovarian cancer should undergo germline BRCA1/2 testing, regardless of age, family history, or clinical features 1
Somatic Testing (Tumor Tissue Sample)
- Sample source: Formalin-fixed paraffin-embedded (FFPE) tumor tissue, fresh tumor biopsy, or malignant ascites 2
- What it detects: Mutations acquired only in tumor cells
- Purpose: Identifies additional BRCA1/2 mutations not present in germline DNA
- Recommendation: Should be performed in women who do not carry a germline BRCA1/2 pathogenic variant 1
Clinical Algorithm for BRCA1/2 Testing
Step 1: At diagnosis, obtain peripheral blood for germline BRCA1/2 testing in all women with epithelial ovarian cancer 1
Step 2: If germline testing is negative, proceed with tumor tissue testing for somatic BRCA1/2 mutations 1
Step 3: Conduct testing in conjunction with genetic counselors familiar with hereditary cancer syndromes 1
Important Practical Considerations
Why Blood for Germline Testing?
Germline mutations are constitutional—present from birth in every cell. Blood provides:
- High-quality DNA that is easily extracted
- Consistent results across laboratories
- The ability to detect both small variants and large genomic rearrangements
Alternative Tumor-First Approaches
Recent research suggests tumor tissue can detect most germline variants 3, 4, with concordance rates of 91.7-99.1%. However, tumor testing may miss some germline large rearrangements (3 out of 8 in one study) 3. The 2020 ASCO guideline recommends traditional germline-first testing from blood 1.
When Tumor Tissue Is Used
If tumor tissue is tested (FFPE specimens or malignant ascites 2), it can identify:
- Both germline and somatic BRCA1/2 mutations
- However, positive tumor results require confirmatory germline blood testing to determine if the mutation is inherited (critical for family cascade testing) 3
Common Pitfalls to Avoid
- Don't confuse sample types: Germline testing requires blood/saliva; tumor testing requires tissue
- Don't skip germline testing: Even if tumor testing is performed first, germline confirmation is essential for family counseling 1
- Don't delay testing: Testing should occur at diagnosis to inform upfront treatment decisions with PARP inhibitors 1
- Don't rely solely on tumor testing for large rearrangements: Some germline copy number variants may not be detected in tumor DNA 3
Timing and Coordination
Testing should be performed at the time of diagnosis 1, as BRCA1/2 status directly impacts treatment decisions in both upfront and recurrent settings with FDA-approved PARP inhibitors 1. The high prevalence of germline BRCA1/2 mutations in ovarian cancer (>10% overall, 22.3% in some series 5, 6) justifies universal testing regardless of family history.